Post hoc analysis of the phase 3 PULSAR trial in treatment-naïve nAMD: on aflibercept 8 mg, 86.6% (8q12) and 78.4% (8q16) kept or extended intervals to week 96; in 8q16, shorter final intervals tended to follow greater baseline CRT or MNV area.
Secondary analysis
Garweg et al. Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension: A Post Hoc 96-Week Analysis of PULSAR